Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8<sup>+</sup> T Cell Responses via CD169<sup>+</sup> Macrophages and cDC1

Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8<sup>+</sup> T Cell Responses via CD169<sup>+</sup> Macrophages and cDC1

Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should therefore comprise a potent antigen and adjuvant. Antigen targeting to splenic CD169<sup>+</sup> macrophages was shown to induce robust CD8<sup>+</sup> T cell responses via antigen tran...

Full description

Bibliographic Details
Main Authors: Joanna Grabowska, Dorian A. Stolk, Maarten K. Nijen Twilhaar, Martino Ambrosini, Gert Storm, Hans J. van der Vliet, Tanja D. de Gruijl, Yvette van Kooyk, Joke M.M. den Haan
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Vaccines
Subjects:
vaccination
liposomes
anti-tumor
CD169 macrophage
cDC1
invariant natural killer T cell
Online Access:https://www.mdpi.com/2076-393X/9/1/56

Internet

https://www.mdpi.com/2076-393X/9/1/56

Similar Items